Moderna, Inc. (NASDAQ:MRNA) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Moderna, Inc. (NASDAQ:MRNA) have earned a consensus rating of “Hold” from the twenty-one ratings firms that are presently covering the firm, Marketbeat.com reports. Four analysts have rated the stock with a sell recommendation, eleven have assigned a hold recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $79.50.

MRNA has been the subject of several recent research reports. Hsbc Global Res upgraded Moderna from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 18th. Wolfe Research assumed coverage on Moderna in a report on Friday, November 15th. They issued an “underperform” rating and a $40.00 price objective on the stock. Royal Bank of Canada reissued a “sector perform” rating and issued a $75.00 price objective on shares of Moderna in a report on Thursday, September 19th. HSBC raised Moderna from a “hold” rating to a “buy” rating and set a $58.00 price objective on the stock in a report on Monday, November 18th. Finally, UBS Group dropped their price objective on Moderna from $140.00 to $108.00 and set a “buy” rating on the stock in a report on Thursday, October 24th.

Insider Transactions at Moderna

In other Moderna news, CFO James M. Mock sold 715 shares of the business’s stock in a transaction on Monday, October 7th. The stock was sold at an average price of $60.12, for a total transaction of $42,985.80. Following the transaction, the chief financial officer now owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. The trade was a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the transaction, the insider now directly owns 19,717 shares in the company, valued at $843,690.43. This trade represents a 6.71 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 3,379 shares of company stock valued at $158,195 over the last ninety days. Insiders own 15.70% of the company’s stock.

Hedge Funds Weigh In On Moderna

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MRNA. Ashton Thomas Private Wealth LLC purchased a new stake in Moderna in the second quarter valued at $26,000. Family Firm Inc. acquired a new position in shares of Moderna in the 2nd quarter valued at $33,000. Hanseatic Management Services Inc. acquired a new position in shares of Moderna in the 2nd quarter valued at $48,000. Plato Investment Management Ltd lifted its stake in shares of Moderna by 230.4% in the 2nd quarter. Plato Investment Management Ltd now owns 413 shares of the company’s stock valued at $49,000 after purchasing an additional 288 shares during the last quarter. Finally, Blue Trust Inc. lifted its stake in shares of Moderna by 365.6% in the 3rd quarter. Blue Trust Inc. now owns 731 shares of the company’s stock valued at $49,000 after purchasing an additional 574 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Stock Down 0.1 %

Shares of MRNA stock opened at $42.82 on Friday. The stock has a 50 day moving average of $48.62 and a 200 day moving average of $85.02. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The stock has a market cap of $16.48 billion, a P/E ratio of -7.36 and a beta of 1.58. Moderna has a twelve month low of $35.80 and a twelve month high of $170.47.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($1.89) by $1.92. The company had revenue of $1.90 billion during the quarter, compared to analysts’ expectations of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. Moderna’s quarterly revenue was up 3.8% on a year-over-year basis. During the same period last year, the business earned ($1.39) earnings per share. As a group, sell-side analysts expect that Moderna will post -9.32 EPS for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.